脂蛋白和大动脉狭窄症:从病理生理学到新兴的药理学药剂
Federica Agnello1,2, Giulia Laterra1,2, Lorenzo Scalia2
1Faculty of Medicine and Surgery, Università degli Studi di Enna "Kore", Piazza dell'Università, 94100 Enna, Italy.
Journal of clinical medicine
|January 10, 2026
概括
脂蛋白 (Lp) 是大动脉狭窄症 (AVS) 发展的关键因素. 降低Lp (a) 的疗法在治疗这种常见的心脏病方面表现有前途.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 遗传学 遗传学 是一个
背景情况:
- 大动脉缩症 (AVS) 是全球最常见的膜性心脏病.
- 目前,对于AVS没有药理疗法,因此需要新的治疗策略.
- 脂蛋白 (Lp) 越来越多地被认为是AVS发病的重要危险因素.
研究的目的:
- 审查目前对Lp (a) 在AVS病理生理学中的作用的理解.
- 评估Lp (a) 在AVS中的诊断和预后价值.
- 探索Lp(a) 降低剂在AVS管理中的治疗潜力.
主要方法:
- 对Lp (a) 和AVS现有研究的文献综述.
- 分析证据,将AVS中的脂质代谢,炎症和化联系起来.
- 检查新兴的Lp (a) 向治疗方法.
主要成果:
- Lp (a) 通过连接脂质代谢,炎症和膜化,在AVS中起因作用.
- Lp(a) 水平是基因决定的和稳定的,这使得它们成为一个可行的治疗目标.
- 新兴的疗法,如反感性寡核酸和siRNA,显示出减少Lp (a) 的潜力.
结论:
- Lp (a) 是AVS发育和进展的关键因素.
- 向Lp (a) 代表了AVS药理治疗的有希望的新途径.
- 降低Lp (a) 的药物可以提供第一个医疗选择,以减缓高风险个体的AVS进展.
相关概念视频
Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Atherosclerosis I: Introduction
868
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
868
Aortic Regurgitation III: Medical Management
385
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
385
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Peripheral Artery Disease I: Introduction
301
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
301
Coronary Artery Disease II: Pathophysiology
359
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
359

